Wall Street brokerages expect that Alcentra Capital Corp (NASDAQ:ABDC) will announce $0.20 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Alcentra Capital’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.21. Alcentra Capital posted earnings per share of $0.25 during the same quarter last year, which suggests a negative year-over-year growth rate of 20%. The firm is expected to issue its next quarterly earnings results on Monday, August 5th.

On average, analysts expect that Alcentra Capital will report full year earnings of $0.81 per share for the current financial year, with EPS estimates ranging from $0.79 to $0.83. For the next financial year, analysts forecast that the firm will post earnings of $0.80 per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Alcentra Capital.

Alcentra Capital (NASDAQ:ABDC) last announced its earnings results on Monday, May 6th. The asset manager reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. Alcentra Capital had a return on equity of 8.84% and a net margin of 14.50%. The company had revenue of $6.43 million for the quarter, compared to analyst estimates of $6.24 million.

Separately, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

Several institutional investors have recently made changes to their positions in ABDC. Mercer Global Advisors Inc. ADV bought a new stake in shares of Alcentra Capital during the 1st quarter valued at about $85,000. Millennium Management LLC bought a new stake in shares of Alcentra Capital during the 4th quarter valued at about $107,000. Squarepoint Ops LLC bought a new stake in shares of Alcentra Capital during the 4th quarter valued at about $165,000. Oppenheimer & Co. Inc. boosted its position in shares of Alcentra Capital by 226.1% during the 1st quarter. Oppenheimer & Co. Inc. now owns 33,257 shares of the asset manager’s stock valued at $249,000 after purchasing an additional 23,059 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Alcentra Capital during the 4th quarter valued at about $265,000. Institutional investors own 35.65% of the company’s stock.

Shares of Alcentra Capital stock traded down $0.01 on Wednesday, hitting $8.28. 20,900 shares of the company’s stock traded hands, compared to its average volume of 36,223. Alcentra Capital has a one year low of $5.58 and a one year high of $8.74. The firm’s fifty day moving average price is $8.34. The company has a market cap of $106.66 million, a P/E ratio of 8.20 and a beta of 0.62.

The firm also recently announced a None dividend, which was paid on Wednesday, July 3rd. Investors of record on Friday, June 28th were given a dividend of $0.33 per share. The ex-dividend date of this dividend was Thursday, June 27th. This represents a dividend yield of 8.55%. Alcentra Capital’s payout ratio is 71.29%.

Alcentra Capital Company Profile

Alcentra Capital Corporation is a business development company specializing in investments in lower middle-market companies. The fund seeks to invest in healthcare, business services, defense, government services, telecom and technology, media, infrastructure maintenance and logistics, and oil and gas services sector.

Recommended Story: What is Put Option Volume?

Get a free copy of the Zacks research report on Alcentra Capital (ABDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alcentra Capital (NASDAQ:ABDC)

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.